A Cas12a variant and its application in gene editing
By constructing the K1065E mutant of FnCas12a, the problem of high off-target rate of Cas12a protein in gene editing was solved, target specificity was improved, the probability of off-target was reduced, the types of gene editing tools were expanded, and the CRISPR/Cas gene editing system was enhanced. application potential.
Patent Information
- Application Number
- CN202211153091.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-21
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-09-21
AI Technical Summary
The existing Cas12a protein has a low off-target rate in gene editing and tolerate base mismatch in some target region sequences, resulting in identification and cleavage of non-complete complementary target regions. How to reduce the off-target probability of CRISPR/Cas gene editing system It is a problem that needs to be solved urgently.
By replacing lysine (K) at site 1065 of FnCas12a with glutamate (E), the K1065E mutant of FnCas12a was constructed to improve its target specificity and reduce the probability of off-targeting.
The K1065E mutant of FnCas12a has higher target specificity than wild-type FnCas12a, is more sensitive to single-base mismatch and double-site mutations, avoids non-specific cleavage, and significantly reduces off-target effects.
Smart Images

Figure CN117737033B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene editing technology, and in particular to a Cas12a variant and an application thereof in gene editing. Background Art
[0002] Since its inception, the gene editing method based on the CRISPR / Cas system has been widely used in basic research, disease diagnosis and clinical treatment. In addition to the CRISPR / Cas9 system, which was first used in gene editing, Cas12a, as a member of the CRISPR II effector protein, has also received widespread attention from the scientific community. Compared with the Cas9 protein, which requires two molecules, crRNA and tracrRNA, to achieve the cleavage of double-stranded DNA molecules, Cas12a only needs a single crRNA induction to complete the effective cleavage of the target double-stranded DNA (such as Figure 1 ). At the same time, the CRISPR / Cas12a protein remains in a catalytically active state after completing the cis-cleavage of the target double-stranded DNA, and then starts the non-targeted trans-cleavage of the single-stranded DNA, which has potential applications in disease and virus detection. In addition, the PAM sequence preferred by Cas9 is usually rich in G, while the PAM sequence preferred by Cas12a is rich in T. This feature can better complement the advantages of Cas9 and broaden the scope of gene editing. At present, only three Cas12a proteins, Francisella tularensisCas12a (FnCas12a), Acidaminococcus sp.Cas12a (AsCas12a) and Lachnospiraceaebacterium Cas12a (LbCas12a), have been reported to have the functions of nuclease and genome editing. Although the off-target rate of the existing wild-type Cas12a is lower than that of Cas9, its off-target problem still exists, that is, Cas12a can tolerate base mismatches in some target region sequences and can recognize and cut non-completely complementary target regions. Therefore, how to reduce the off-target probability of the CRISPR / Cas gene editing system is an urgent problem to be solved. Summary of the invention
[0003] In view of the defects in the prior art, the present invention proposes a Cas12a variant and its application in gene editing. The present invention focuses on FnCas12a, replaces the lysine (K) at position 1065 of FnCas12a with glutamic acid (E), and obtains a new K1065E mutant, which improves its targeting specificity and reduces off-target compared with the wild-type FnCas12a.
[0004] The present invention provides a Cas12a variant, the amino acid sequence of the Cas12a variant is shown in SED ID NO.1, and the Cas12a variant protein has an increased DNA cleavage selectivity relative to the corresponding wild-type Cas12a protein.
[0005] The present invention also provides a recombinant expression vector, which expresses the Cas12a variant.
[0006] Furthermore, the recombinant expression vector includes any one of a plasmid vector, a viral vector and a phage vector.
[0007] The present invention also provides a recombinant bacterium or a recombinant cell line or a recombinant virus, comprising the recombinant expression vector.
[0008] The present invention also provides a recombinant virus, which is obtained by packaging the viral vector, and the recombinant virus includes an adenovirus or a lentivirus expressing the Cas12a variant.
[0009] The present invention also provides the use of the Cas12a variant, the recombinant expression vector, the recombinant bacteria or recombinant cell line and the recombinant virus in gene editing.
[0010] The present invention also provides a CRISPR / Cas12a gene editing system comprising the Cas12a variant.
[0011] Furthermore, the system also includes: crRNA targeting the target gene.
[0012] The present invention also provides a method for gene editing of a target gene in a receptor, wherein the target gene in the receptor is gene edited by means of a CRISPR / Cas12a system, wherein the method comprises providing a Cas12a variant by introducing the recombinant expression vector into the receptor.
[0013] In summary, compared with the prior art, the present invention achieves the following technical effects:
[0014] The present invention improves the targeting specificity of FnCas12a for double-stranded DNA cutting and reduces its off-target probability by constructing the K1065E mutant of FnCas12a. The K1065E mutant of FnCas12a of the present invention has a higher targeting specificity than wild-type FnCas12a. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0016] Figure 1 It is a schematic diagram of Cas12a in the prior art.
[0017] Figure 2 Single mismatch in vitro cleavage experiment of wild-type and K1065E mutant FnCas12a proposed in the embodiment of the present invention.
[0018] Figure 3 Double mismatch in vitro cleavage experiment of wild-type and K1065E mutant FnCas12a proposed in the embodiment of the present invention.
[0019] Figure 4 In vitro cleavage experiments on non-classical PAM sequences of wild-type and K1065E mutant FnCas12a proposed in embodiments of the present invention. DETAILED DESCRIPTION
[0020] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work should fall within the scope of protection of the present invention.
[0021] The present invention provides a novel FnCas12a mutant K1065E, the amino acid sequence of which is shown in SEQ ID NO.1. The total length of the amino acid sequence protein of the K1065E mutant of FnCas12a is 1326 amino acids. In vitro double-stranded DNA digestion experiments show that the mutant FnCas12a is more sensitive to single base mismatch sequences than wild-type FnCas12a. That is, a single base mismatch near the protospacer adjacent motif (PAM) region can effectively reduce potential off-target effects. Further experiments show that the K1065E mutant can circumvent the nonspecific cutting of the wild-type FnCas12a protein at the 5th and 6th double-site mutations, proving that the K1065E mutant has higher targeting specificity.
[0022] Unless otherwise specified, all reagents, raw materials, technical services and instruments used in the present invention can be purchased on the market.
[0023] Example
[0024] The wild-type and K1065E mutant FnCas12a were used to cut the plasmids at the WT site (no mismatch) and mismatch sites 1 to 7, respectively. The specific operation is as follows, which is divided into two parts:
[0025] The first part is the construction of DNA products with mismatched bases;
[0026] The second part is an in vitro Cas12a cleavage experiment.
[0027] (I) Construction of DNA products with base mismatches
[0028] After annealing, the base-complementary oligonucleotides are introduced between the EcoRⅠ and HindIII restriction sites of the plasmid pUC19. The target chain of the oligonucleotide is complementary to the crRNA of FnCas12a, contains a single base mismatch, or contains a double base mismatch, and the sequence is shown in Table 1. The pUC19 plasmid after enzyme digestion and ligation is transferred into the competent Escherichia coli, plated, and selected for sequencing of the Escherichia coli monoclonal clone to determine the sequence of the recombinant plasmid. After all the plasmids are constructed, 2 μg of plasmid is taken, added to 1× rCutSmart buffer, and 40 units of SspI-HF restriction endonuclease are used to react at 37°C for 2 hours to fully linearize the plasmid, and the final reaction volume is 20 μL. Subsequently, heat at 65°C for 20 minutes to inactivate the SspI-HF enzyme. The DNA product used for Cas12a cutting can be obtained.
[0029] Table 1 crRNA and oligonucleotide sequences
[0030]
[0031]
[0032]
[0033] (II) In vitro cleavage experiment of Cas12a
[0034] First, FnCas12a and crRNA were incubated at 37°C for 10 minutes in the presence of magnesium ions, and then the DNA product obtained in (a) was added to perform a cleavage reaction. The specific reaction ratio is shown in Table 2:
[0035] Table 2
[0036] The stock solution is 10 μM FnCas12a Add 5 μL (final concentration 2.5 μM) The stock solution is 10 μM crRNA Add 2 μL (final concentration 1 μM) <![CDATA[The mother liquor is 100 mM MgCl2]]> Add 1 μL (final concentration 5 mM) Linearized DNA Add 250ng Nuclease-free water Make up to a final volume of 20 μL
[0037] After the cleavage reaction was allowed to react at 37°C for 10 minutes, EDTA and proteinase K were added to a final concentration of 80 mM and 0.8 mg / mL, respectively, and incubated at 37°C for 30 minutes to terminate the cleavage reaction. The cleaved product was added to 6× DNA loading buffer, loaded onto an agarose gel, and voltage was applied to separate it, followed by photographing.
[0038] The results of single mismatch in vitro cleavage are as follows Figure 2 As shown, both the wild-type and K1065E mutant FnCas12a can completely cut the non-mismatched plasmid to obtain cleavage products 1 and 2. However, the wild-type FnCas12a still cuts the mismatch sites 1 to 7, while the K1065E mutant FnCas12a cuts less mismatch sites 1 to 7, indicating that it has higher specificity than the wild-type.
[0039] The results of double mismatch in vitro cleavage are as follows Figure 3 As shown, the wild-type and K1065E mutant FnCas12a have significant differences in the cutting properties of the consecutive double mutations at positions 5 and 6. The wild-type FnCas12a protein has a high nonspecific cutting activity for the consecutive double mutations at positions 5 and 6, but the K1065E mutant FnCas12a is almost unable to cut the DNA double strands containing the consecutive double mutations at positions 5 and 6, indicating that it has higher specificity than the wild-type.
[0040] The results of in vitro cleavage of non-classical PAM sequences are as follows Figure 4 As shown, the wild type and K1065E mutant FnCas12a have significant differences in cutting specificity for other PAM sequences (such as CTTN, TCTN, TTCN, CCTN) of non-classical PAM (TTTN). The K1065E mutant FnCas12a protein can effectively reduce the nonspecific cutting of the three PAM sequences of TCTN, TTCN, and CCTN, indicating that it has higher specificity than the wild type.
[0041] In summary of the above embodiments, the Cas12a variants of the present invention have higher specificity than the wild type for single mismatches, double mismatches or non-classical PAM sequences. The Cas12a variants can further expand the types of gene editing tools and play an important role in the application of CRISPR / Cas gene editing systems.
[0042] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A Cas12a variant, characterized in that The amino acid sequence of the Cas12a variant is shown in SED ID NO.1, and the Cas12a variant protein has an increased DNA cleavage selectivity relative to the corresponding wild-type Cas12a protein.
2. A recombinant expression vector, characterized in that: The recombinant vector expresses the Cas12a variant described in claim 1.
3. The recombinant expression vector according to claim 2, characterized in that The recombinant expression vector includes any one of a plasmid vector, a virus vector and a phage vector.
4. A recombinant bacterium, a recombinant cell line or a recombinant virus, characterized in that: Comprising the recombinant expression vector according to claim 2.
5. A recombinant virus, characterized in that The recombinant virus is obtained by packaging the viral vector described in claim 3, and the recombinant virus includes an adenovirus or a lentivirus expressing the Cas12a variant described in claim 1.
6. Use of the Cas12a variant described in claim 1, the recombinant expression vector described in any one of claims 2 to 3, the recombinant bacteria or recombinant cell line described in claim 4, and the recombinant virus described in claim 5 in the preparation of a gene editing kit.
7. A CRISPR / Cas12a gene editing system comprising the Cas12a variant described in claim 1.
8. The CRISPR / Cas gene editing system according to claim 7, characterized in that The system also includes: crRNA targeting the target gene.
